Bloqueo anestésico del nervio occipital mayor en el tratamiento de las cefaleas. Revisión de la evidencia / Greater occipital nerve block in the treatment of headaches. Review of evidence

Introducción Los bloqueos anestésicos de nervios pericraneales han constituido un tratamiento habitual de múltiples cefaleas. El más utilizado en la práctica clínica habitual y que cuenta con mayor evidencia que avale su efectividad es el bloqueo del nervio occipital mayor. Métodos búsqueda en Pubmed de Meta-Analysis/Systematic Review de los últimos 10 años, seleccionando para su revisión aquellos metaanálisis, y en su defecto revisiones sistemáticas, acerca del bloqueo del nervio occipital mayor en el tratamiento de las cefaleas. Resultados Se obtuvieron 95 trabajos, 13 incluyeron los criterios de inclusión. Conclusión El bloqueo del occipital mayor es una técnica eficaz y segura, fácil de realizar, y que ha mostrado su utilidad en migraña, cefalea en racimos, cefalea cervicogénica y pospunción lumbar. No obstante, hacen falta más estudios que aclaren su eficacia a largo plazo, su lugar en el tratamiento habitual, la posible diferencia entre diversos anestésicos, la posología más conveniente y el papel del uso concomitante de corticoides (AU)

Introduction Peripheral nerve blocks have been a common treatment for multiple headaches. By far, the greater occipital nerve block is the most used and with the stronger body of evidence in routine clinical practice. Methods We searched Pubmed Meta-Analysis/Systematic Review, in the last 10 years. Of these results, meta-analyses, and in the absence of these systematic reviews, assessing Greater Occipital Nerve Block in headache has been selected for review. Results We identified 95 studies in Pubmed, 13 that met the inclusion criteria. Conclusion Greater occipital block is an effective and safe technique, easy to perform and which has shown its usefulness in migraine, cluster headache, cervicogenic headache and Post-dural puncture headache. However, more studies are needed to clarify its long-term efficacy, its place in clinical treatment, the possible difference between different anaesthetics, the most convenient dosage and the role of concomitant use of corticosteroids (AU)

[Greater occipital nerve block in the treatment of headaches. Review of evidence]. / Bloqueo anestésico del nervio occipital mayor en el tratamiento de las cefaleas. Revisión de la evidencia.

INTRODUCTION: Peripheral nerve blocks have been a common treatment for multiple headaches. By far, the greater occipital nerve block is the most used and with the stronger body of evidence in routine clinical practice. METHODS: We searched Pubmed Meta-Analysis/Systematic Review, in the last 10 years. Of these results, meta-analyses, and in the absence of these systematic reviews, assessing Greater Occipital Nerve Block in headache has been selected for review. RESULTS: We identified 95 studies in Pubmed, 13 that met the inclusion criteria. CONCLUSION: Greater occipital block is an effective and safe technique, easy to perform and which has shown its usefulness in migraine, cluster headache, cervicogenic headache and Post-dural puncture headache. However, more studies are needed to clarify its long-term efficacy, its place in clinical treatment, the possible difference between different anaesthetics, the most convenient dosage and the role of concomitant use of corticosteroids.

Riesgo de infección por SARS-CoV-2 y resultados clínicos en pacientes con esclerosis múltiple en la Rioja (España) / Risk of SARS-CoV-2 infection and clinical outcomes in multiple sclerosis patients in La Rioja (Spain)

No disponible

El holobionte enfermo, el ejemplo de la esclerosis múltiple / Disease of the holobiont, the example of multiple sclerosis

En los últimos años se ha producido una revolución en torno al papel de la microbiota en diferentes enfermedades, la mayoría dentro del espectro de las inflamatorias y autoinmunes, asociado al desarrollo de la metagenómica y al concepto de holobionte, entendido como el conjunto formado por los organismos superiores y su microbiota. Concretamente, en la esclerosis múltiple, existe múltiple evidencia acerca del papel de la microbiota en la encefalomielitis autoinmune experimental, modelo animal de la enfermedad y se han publicado en los últimos años diversos artículos acerca de las diferencias en la microbiota intestinal entre pacientes enfermos de esclerosis múltiple y sujetos control. En este artículo revisamos el concepto de holobionte y las funciones de la microbiota dentro del mismo, así como la evidencia acumulada en el papel de la microbiota en la encefalomielitis autoinmune experimental y en la esclerosis múltiple. A día de hoy, existe una amplia evidencia científica del papel de la microbiota en la génesis, prevención y tratamiento de la encefalomielitis autoinmune experimental en base fundamentalmente a tres pilares inmunológicos, el equilibrio Th1-Th17/Th2, las células Treg y la inmunidad humoral. Así mismo está bien documentado que existen diferencias en la microbiota de pacientes con EM que se asocian a una diferente expresión de genes relacionados con la inflamación

In recent years there has been a revolution regarding the role of the microbiota in different diseases, most of them within the spectrum of inflammatory and autoimmune diseases, associated with the development of metagenomics and the concept of holobiont, a large organism together with its microbiota. Specifically, in Multiple Sclerosis, multiple evidence points to the role of the microbiota in experimental autoimmune encephalomyelitis, animal model of the disease, and several articles have been published in recent years about differences in intestinal microbiota among patients with multiple sclerosis and control subjects. We review in this article the concept of holobiont and the gut microbiota functions, as well as the evidence accumulated about the role of the microbiota in experimental autoimmune encephalomyelitis and multiple sclerosis. Nowadays, there is a lot of evidence showing the role of the microbiota in the genesis, prevention and treatment of experimental autoimmune encephalomyelitis based mainly on three immunological pillars, the Th1-Th17 / Th2 balance, the Treg cells and the humoral immunity. It is also well documented that there are differences in the microbiota of patients with MS that are associated with a different expression of genes related to inflammation

Disease of the holobiont, the example of multiple sclerosis. / El holobionte enfermo, el ejemplo de la esclerosis múltiple.

In recent years there has been a revolution regarding the role of the microbiota in different diseases, most of them within the spectrum of inflammatory and autoimmune diseases, associated with the development of metagenomics and the concept of holobiont, a large organism together with its microbiota. Specifically, in Multiple Sclerosis, multiple evidence points to the role of the microbiota in experimental autoimmune encephalomyelitis, animal model of the disease, and several articles have been published in recent years about differences in intestinal microbiota among patients with multiple sclerosis and control subjects. We review in this article the concept of holobiont and the gut microbiota functions, as well as the evidence accumulated about the role of the microbiota in experimental autoimmune encephalomyelitis and multiple sclerosis. Nowadays, there is a lot of evidence showing the role of the microbiota in the genesis, prevention and treatment of experimental autoimmune encephalomyelitis based mainly on three immunological pillars, the Th1-Th17 / Th2 balance, the Treg cells and the humoral immunity. It is also well documented that there are differences in the microbiota of patients with MS that are associated with a different expression of genes related to inflammation.

Botulinum toxin in trigeminal neuralgia. / Toxina botulínica en la neuralgia del trigémino.

INTRODUCTION: Trigeminal neuralgia is one of the most disabling facial pain syndromes, with a significant impact on patients' quality of life. Pharmacotherapy is the first choice for treatment but cases of drug resistance often require new strategies, among which various interventional treatments have been used. In recent years a new therapeutic strategy consisting of botulinum toxin has emerged, with promising results. DEVELOPMENT: We reviewed clinical cases and case series, open-label studies and randomized clinical trials examining the use of botulinum toxin for drug-refractory trigeminal neuralgia published in the literature. CONCLUSIONS: The administration of botulinum toxin has proven to be a safe and effective therapeutic strategy in patients with drug-refractory idiopathic trigeminal neuralgia, but many questions remain unanswered as to the precise role of botulinum toxin in the treatment of this disease.

Spinal cord toxoplasmosis in human immunodeficiency virus infection/acquired immunodeficiency syndrome.

Neurological complications in patients with human immunodeficiency virus infection/acquired immunodeficiency syndrome (HIV/AIDS) are still common, even in the era of highly active antiretroviral therapy. Opportunistic infections, immune reconstitution, the virus itself, antiretroviral drugs and neurocognitive disorders have to be considered when establishing the differential diagnosis. Toxoplasmic encephalitis remains the major cause of space-occupying lesions in the brain of patients with HIV/AIDS; however, spinal cord involvement has been reported infrequently. Here, we review spinal cord toxoplasmosis in HIV infection and illustrate the condition with a recent case from our hospital. We suggest that most patients with HIV/AIDS and myelitis with enhanced spine lesions, multiple brain lesions and positive serology for Toxoplasma gondii should receive immediate empirical treatment for toxoplasmosis, and a biopsy should be performed in those cases without clinical improvement or with deterioration.